Farxiga Approved for Patients With CKD at Risk of Progression
The approval was based on data from the DAPA-CKD trial, which compared dapagliflozin, an SGLT2 inhibitor, to placebo on renal outcomes and cardiovascular mortality in patients with CKD.
Diana Ernst, RPh
Editorial Director
Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.
